nach oben

Cancer Causes & Control

Erschienen in:

01.01.2010 | Original paper

The impact of changes in hormone therapy on breast cancer incidence in the US population

verfasst von: Nathan J. Coombs, Kathleen A. Cronin, Richard J. Taylor, Andrew N. Freedman, John Boyages

Erschienen in: Cancer Causes & Control | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study combines population changes in hormone therapy (HT) use with reported relative risks to estimate directly the impact of reductions in HT use on US breast cancer incidence.

Methods

Using breast cancer incidence rates and prevalence estimates of HT use, the breast cancer incidence in HT users and non-users was derived. Attributable fraction calculations used risk data from the Million Women Survey (MWS), Collins’ meta-analysis (CMA), and the initial or later data from the Women’s Health Initiative (WHI) study.

Results

Between 2000 and 2005, HT use fell from 25.0 to 11.3%. The reported breast cancer incidence (in women aged 40–79) fell 8.8%. Derived incidence rates among non-users of HT remained unchanged (MWS or later WHI data) or slightly lower (initial WHI and CMA data), suggesting reductions in incidence are almost entirely (MWS or later WHI data) or partially (initial WHI or CMA data) due to reduced HT use.

Conclusion

Changes in reported breast cancer incidence may be partially or largely explained by changes in HT use in the US population.

Howe HL, Wu X, Ries LA et al (2006) Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107(8):1711–1742CrossRefPubMed

Coombs NJ, Taylor R, Wilcken N, Boyages J (2005) HRT and breast cancer: impact on population risk and incidence. Eur J Cancer 41(12):1775–1781CrossRefPubMed

Chlebowski RT, Hendrix SL, Langer RD, WHI Investigators et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253CrossRefPubMed

Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women’s Health Initiative Investigators et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed

Stefanick ML, Anderson GL, Margolis KL, WHI Investigators et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657CrossRefPubMed

Chlebowski RT, Kuller LH, Prentice RL et al (2009) Breast Cancer after use of estrogen plus progestin I post-menopausal women. N Engl J Med 360(6):573–587CrossRefPubMed

Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427CrossRefPubMed

Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140(3):184–188PubMed

Coombs NJ, Boyages J (2005) Changes in HT prescriptions in Australia since 1992. Aust Fam Physician 34(8):697–698PubMed

10.

Ries LAG, Melbert D, Krapcho M et al. (eds) (2008) SEER cancer statistics review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008

11.

Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed

12.

Taylor R, Boyages J (2001) Estimating risk of breast cancer from population incidence affected by widespread mammographic screening. J Med Screen 8(2):73–76CrossRefPubMed

13.

Feuer EJ, Wun LM (1992) How much of the recent rise in breast cancer incidence can be explained by increase in mammography utilization? Am J Epidemiol 136(12):1423–1436PubMed

14.

National Health Interview Survey (2007) National Center for Health Statistics, 2000 and 2005 datasets. www.cdc.gov/nchs/nhis.htm. Accessed 22 July 2007

15.

Hunt K, Vessey M, McPherson K, Coleman M (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94(7):620–635PubMed

16.

Grady D, Rubin SM, Petitti DB et al (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117(12):1016–1037PubMed

17.

Buist DS, Newton KM, Miglioretti DL et al (2004) Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104(5pt1):1042–1050PubMed

18.

Taylor R, Boyages J (2000) Absolute risk of breast cancer for Australian women with a family history. Aust N Z J Surg 70:725–731CrossRefPubMed

19.

Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormone treatment. Hum Reprod Update 11(6):545–560CrossRefPubMed

20.

Coombs NJ, Taylor R, Wilcken N, Boyages J (2005) Hormone replacement therapy and breast cancer: estimate of risk. BMJ 331(7512):347–349CrossRefPubMed

21.

National Center for Health Statistics. Health, United States 2006. With chartbook on trends in the health of Americans. Hyattsville, MD

22.

Armitage P, Berry G (1994) Statistical methods in medical research, 3rd edn. Blackwell, London

23.

Shapiro S (2004) The million women study: potential biases do not allow uncritical acceptance of the data. Climacteric 7(1):3–7CrossRefPubMed

24.

Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112(1):130–134CrossRefPubMed

25.

Coombs NJ, Taylor R, Wilcken N, Fiorica J, Boyages J (2005) Hormone replacement therapy and breast cancer risk in California. Breast J 11(6):410–415CrossRefPubMed

26.

Carney PA, Miglioretti DL, Kankasas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175PubMed

27.

Carney PA, Tosteson AN, Titus-Ernstoff L et al (2006) Hormone therapies in women aged 40 and older: prevalence and correlates of use. Maturitas 53(1):65–76CrossRefPubMed

28.

Anderson GL, Chlebowski RT, Rossouw JE et al (2006) Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 55(2):103–115CrossRefPubMed

29.

Graubard BI, Flegal KM, Williamson DF, Gail MH (2007) Estimation of attributable number of deaths and standard errors from simple and complex sampled cohorts. Stat Med 26(13):2639–2649CrossRefPubMed

30.

Beral V, Reeves G, Banks E (2005) Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG 112(6):692–695CrossRefPubMed

Titel: The impact of changes in hormone therapy on breast cancer incidence in the US population
verfasst von: Nathan J. Coombs
Kathleen A. Cronin
Richard J. Taylor
Andrew N. Freedman
John Boyages
Publikationsdatum: 01.01.2010
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 1/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9437-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The impact of changes in hormone therapy on breast cancer incidence in the US population

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women

The association between fruit and vegetable consumption and HPV viral load in high-risk HPV-positive women with cervical intraepithelial neoplasia

trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II

Metabolic syndrome components and colorectal adenoma in the CLUE II cohort

Beliefs about the causes of breast and colorectal cancer among women in the general population

Low cancer incidence rates in Ohio Amish

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie